Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $33M seed (Mar 2026). Owkin Dx spinout. Multimodal oncology AI analyzing pathology images + clinical data for treatment decisions. Positioned against Tempus and Foundation Medicine.
Waiv is a digital pathology AI company spun out of Owkin's diagnostic unit in March 2026 with a $33 million seed round, inheriting Owkin's proven multimodal oncology AI stack that has been validated in multiple peer-reviewed publications and clinical collaborations with major academic medical centers. The platform analyzes H&E-stained pathology slide images combined with genomic, clinical, and outcomes data to extract prognostic and predictive biomarkers that help oncologists select optimal treatments for individual cancer patients.
Benchling is a life sciences R&D cloud platform with ~$200M+ ARR. Series E startup valued at ~$6.1B. Trusted by Pfizer, Genentech, and 1,000+ biotech/pharma teams. HQ: San Francisco.
Benchling is a cloud-based research and development platform purpose-built for the life sciences industry, founded in 2012 by Sajith Wickramasekara and Ashu Singhal as a Y Combinator alumnus. The company offers an integrated suite of tools including electronic lab notebooks (ELN), laboratory information management systems (LIMS), molecular biology design tools, and data management platforms, all connected in a unified cloud environment.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.